このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

CD4数が300未満または300以上で健康な対照集団を持つHIV患者における組換え水痘帯状疱疹ウイルスワクチンの安全性と免疫原性

CD4数が300未満または300以上で、健康な対照集団を持つHIV感染者における組換え水痘帯状疱疹ウイルスワクチン(RZV)の安全性と免疫原性の第1/2相非盲検試験

Background:

Shingles is a painful, blistering rash caused by the same virus that causes chickenpox. Shingrix is a vaccine approved to prevent shingles in healthy adults over age 50 and in immunocompromised adults over age 18. Researchers want to learn more about how people with HIV respond to Shingrix.

Objective:

To learn how Shingrix affects the immune response in people with HIV.

Eligibility:

People aged 18 years and older with HIV. Healthy people aged 50 years or older are also needed.

Design:

Participants will have at least 4 clinic visits in 1 year.

Participants will be screened. They will have a physical exam with blood and urine tests.

At their first visit, participants will receive Shingrix as a shot in the upper arm. They will have a rectal swab; a cotton swab will be inserted into the rectum and rotated gently to collect bacteria.

Participants will receive a second shot of Shingrix 2 months after the first one. They will visit the clinic again 3 and 12 months after the first shot.

Participants will receive a 28-day memory tool. They will write down their symptoms between clinic visits. They will have up to 4 phone calls to talk about side effects of the shot.

Participants may undergo apheresis: They will lie still while blood is drawn from a needle in one arm. The blood will pass through a machine that separates out the white blood cells. The remaining blood will be given back through a second needle in their other arm.

調査の概要

状態

募集

条件

詳細な説明

Study Description:

This phase 1/2 open-label study will evaluate the safety and immunogenicity of the Shingrix recombinant varicella zoster virus vaccine (RZV) in people with HIV (PWH) aged 18 years and older and healthy volunteers aged 50 years and older. Shingrix will be administered by intramuscular (IM) injection during visits at months 0 and 2, and blood will be collected prior to each dose and at follow-up visits at months 3 and 12. Study evaluations will include assessment of adverse events (AEs) by physical examination, safety laboratory evaluations, and participant memory tool, and assessment of response in research immunogenicity assays on blood.

Objectives:

Primary Objective:

-Assess vaccine immunogenicity after administration of a full Shingrix series schedule in PWH based upon CD4 count < 300 and >= 300.

Secondary Objectives:

  • Assess vaccine immunogenicity after administration of a full Shingrix series schedule in PWH by age (< 50 and >= 50 years).
  • Compare vaccine immunogenicity in PWH versus healthy volunteers.
  • Evaluate grade 3 and 4 safety responses in PWH, based upon CD4 count (< 300 and >= 300), and healthy volunteers.
  • Evaluate grade 3 and 4 safety responses in PWH, based upon age (< 50 and >= 50), and healthy volunteers.

Tertiary/Exploratory Objectives:

  • Compare immune cell responses in PWH, based upon CD4 count (< 300 and >= 300), and healthy volunteers.
  • Compare immune cell responses in PWH, based upon age (< 50 and >= 50 years), and healthy volunteers.
  • Assess vaccine immunogenicity by varicella zoster serostatus.
  • Assess zoster reactivation.
  • Correlate the microbiome profile with vaccine responses.

Endpoints:

Primary Endpoint:

-Fold change of anti-glycoprotein gE (anti-gE) antibody concentrations evaluated regularly through the end of study (months 3 and 12) by CD4 count (< 300 and >= 300) run by GlaxoSmithKline (GSK).

Secondary Endpoints:

  • Fold change of anti-gE antibody concentrations evaluated regularly through the end of study (months 3 and 12) by age (< 50 and >= 50) run by GSK.
  • Fold change of anti-gE antibody concentrations evaluated regularly through the end of study (months 3 and 12) in PWH and healthy volunteers run by GSK.
  • Grade 3 and/or Grade 4 Shingrix AEs (solicited and unsolicited local and systemic).

Tertiary/Exploratory Endpoints:

  • T-cell assays and phenotypes evaluated regularly through end of study.
  • Varicella zoster serostatus as determined by IgG and IgM antibody levels.
  • Number of episodes and severity of zoster reactivation (including extradermatomal complications such as neurologic or ophthalmologic complications and adverse sequelae such as post herpetic neuralgia).
  • Baseline microbiome profile.

研究の種類

介入

入学 (推定)

225

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • 募集
        • National Institutes of Health Clinical Center
        • コンタクト:
          • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
          • 電話番号:TTY dial 711 800-411-1222
          • メール:ccopr@nih.gov

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

  • INCLUSION CRITERIA:

General Inclusion Criteria:

Individuals must meet all of the following criteria to be eligible for study participation:

  • Able to provide informed consent.

  • Participants of childbearing potential must agree to use at least 1 acceptable method of contraception when engaging in sexual activities that can result in pregnancy, beginning at screening through month 3. Acceptable methods of contraception include the following:

    • Hormonal contraception.
    • Male or female condom.
    • Diaphragm or cervical cap with a spermicide.
    • Intrauterine device.
  • Has a primary care provider.

Additional Inclusion Criteria for People with HIV:

  • PWH must also meet all the following criteria to be eligible for study participation:
  • >= 18 years of age.
  • Seropositive for HIV-1 (documented or confirmed at screening).
  • Documented viral load < 100 copies/mL within 90 days of screening and documented viral suppression defined as viral load consistently <100 copies/mL with at least one documented viral load < 40 copies/mL within 12 months prior to screening.
  • Currently on a stable antiretroviral regimen (minimum of 6 months of a stable ART regimen; changes for side effects, drug interaction, or convenience allowed), or is an elite controller (maintains undetectable viral loads in the absence of any treatment for a period of 12 months prior to screening visit).
  • No active/uncontrolled opportunistic infections (patients on chronic maintenance therapy would be considered as controlled).

Additional Inclusion Criteria for Healthy Volunteers:

Healthy volunteers must also meet all of the following criteria to be eligible for study participation:

  • >= 50 years of age.
  • No uncontrolled chronic medical issues that per the discretion of the PI or designee would compromise the safety of the research participant.
  • No underlying immunodeficiencies (including negative HIV test at screening).

EXCLUSION CRITERIA:

Individuals meeting any of the following criteria will be excluded from study participation:

  • Previous receipt of Shingrix vaccine at any time.
  • Receipt of Zostavax within the past 12 months.
  • History of severe allergic reaction to any component of Shingrix.
  • Diagnosed varicella or herpes zoster episode within the past 1 month. Subject will be eligible for SHINGRIX vaccine once symptoms of herpes zoster episode have resolved.
  • Immunocompromised (other than HIV for the PWH cohort) within the past 6 months (eg, due to a malignancy other than skin cancer).
  • Current moderate or severe acute illness (ie, febrile illness, seizure, myocardial infarction, cerebrovascular accident, pulmonary embolism) that in the opinion of the principal investigator, would make the subject unsuitable for the study.
  • Pregnancy or breastfeeding.
  • Receipt of an investigational agent, investigational vaccine, or licensed live virus vaccine within 30 days prior to screening.
  • Planned receipt of any vaccine (investigational or ACIP-recommended) between months 0 and 2 except for the tetanus, diphtheria, and pertussis vaccine [TDaP], Pneumovax, inactivated influenza vaccines, and COVID-19 vaccine which may be given at least 8 days before and/or at least 14 days after each study agent injection (at month 0/month 2).
  • Administration of immunoglobulins or any blood products within 90 days preceding the first dose of vaccine or planned administration during the study period.
  • Chronic administration (>= 15 consecutive days) of immunosuppressive or other immune-modifying drugs within 6 months before screening. (Prednisone < 20 mg/day or equivalent, corticosteroid nasal spray or inhaler, and topical steroids are not exclusionary).
  • Uncontrolled psychiatric disease per physician evaluation, current substance use, or inappropriate conduct unsuitable for a research study.
  • Any condition that could compromise, in the investigator's opinion, the participant's safety or the study outcomes.

Participants will be selected in an equitable manner from the available pool of potentially eligible individuals, without regard to factors such as sex, race, ethnicity, socioeconomic status, etc, except for age.

Medical record review may be used for determining eligibility. If a clinical laboratory evaluation is available for review at the screening timepoint, but was obtained prior to protocol consent, the laboratory test does not have to be repeated for the purposes of confirming eligibility under the protocol.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Shingrix

Shingrix will be administered in two 0.5-mL doses approximately 2 months apart.

Shingrix is a recombinant, adjuvanted vaccine for prevention of herpes zoster. It is supplied as lyophilized recombinant VZV surface gE antigen for reconstitution with AS01B adjuvant suspension. Each Shingrix dose will be 0.5mL and administered by IM injection in the deltoid region of the upper arm.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Fold change of anti-gE antibody concentrations evaluated regularly through the end of study (months 3 and 12) by CD4 count (< 300 and >= 300)
時間枠:Months 3 and 12

Assess vaccine immunogenicity after administration of a full Shingrix series schedule in PWH based upon CD4 count < 300 and >= 300.

Months 3 and 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Fold change of anti-gE antibody concentrations evaluated regularly through the end of study in PWH and healthy volunteers
時間枠:Months 3 and 12

Compare vaccine immunogenicity in PWH versus healthy volunteers.

Months 3 and 12
Grade 3 and/or Grade 4 Shingrix ARs (solicited and unsolicited local and systemic).
時間枠:Through the end of the study

Evaluate grade 3 and 4 safety responses in PWH, based upon age (< 50 and >= 50), and healthy volunteers.

Through the end of the study
Grade 3 and/or Grade 4 Shingrix ARs (solicited and unsolicited local and systemic).
時間枠:Through the end of the study

Evaluate grade 3 and 4 safety responses in PWH, based upon CD4 count (< 300 and >= 300), and healthy volunteers.

Through the end of the study
Fold change of anti-gE antibody concentrations evaluated regularly through the end of study by age (< 50 and >= 50)
時間枠:Months 3 and 12

Assess vaccine immunogenicity after administration of a full Shingrix series schedule in PWH by age (< 50 and >= 50 years).

Months 3 and 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Maura M Manion, M.D.、National Institute of Allergy and Infectious Diseases (NIAID)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年3月13日

一次修了 (推定)

2027年2月1日

研究の完了 (推定)

2027年10月1日

試験登録日

最初に提出

2022年10月8日

QC基準を満たした最初の提出物

2022年10月13日

最初の投稿 (実際)

2022年10月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年7月23日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する